Ashish Noronha, PhD

Title(s)Postdoctoral Scholar, Urology
SchoolSchool of Medicine
Address1450 Third Street, #319
San Francisco CA 94158
PronounsHe/Him/His
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    As a Postdoctoral Scholar in the Urology department at UCSF, my research has been dedicated to understanding and addressing drug resistance mechanisms in breast cancer and other aggressive tumors. Currently, my research focuses on uncovering novel molecular mechanisms that underlie the emergence of drug-tolerant persister cells, with a specific emphasis on enhancing the efficacy of treatments for ER-positive breast cancer patients. During my research journey, I have co-authored research publications that delve into the intricate interactions between oncoproteins and transcription factors. Additionally, my work has explored the role of targeted therapies and therapeutic antibodies in the context of cancer treatment. Through my work, I have been able to identify potential therapeutic targets and develop strategies aimed at overcoming resistance to existing therapies.

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Small-molecule RNA therapeutics to target prostate cancer. Cancer Cell. 2025 May 12; 43(5):841-855.e8. Kuzuoglu-Ozturk D, Nguyen HG, Xue L, Figueredo E, Subramanyam V, Liu I, Bonitto K, Noronha A, Dabrowska A, Cowan JE, Oses-Prieto JA, Burlingame AL, Worland ST, Carroll PR, Ruggero D. PMID: 40118049.
      View in: PubMed   Mentions:    Fields:    
    2. Computational optimization of antibody humanness and stability by systematic energy-based ranking. Nat Biomed Eng. 2024 Jan; 8(1):30-44. Tennenhouse A, Khmelnitsky L, Khalaila R, Yeshaya N, Noronha A, Lindzen M, Makowski EK, Zaretsky I, Sirkis YF, Galon-Wolfenson Y, Tessier PM, Abramson J, Yarden Y, Fass D, Fleishman SJ. PMID: 37550425; PMCID: PMC10842793.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    3. AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer. Cancer Discov. 2022 11 02; 12(11):2666-2683. Noronha A, Belugali Nataraj N, Lee JS, Zhitomirsky B, Oren Y, Oster S, Lindzen M, Mukherjee S, Will R, Ghosh S, Simoni-Nieves A, Verma A, Chatterjee R, Borgoni S, Robinson W, Sinha S, Brandis A, Kerr DL, Wu W, Sekar A, Giri S, Chung Y, Drago-Garcia D, Danysh BP, Lauriola M, Fiorentino M, Ardizzoni A, Oren M, Blakely CM, Ezike J, Wiemann S, Parida L, Bivona TG, Aqeilan RI, Brugge JS, Regev A, Getz G, Ruppin E, Yarden Y. PMID: 35895872; PMCID: PMC9627128.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansAnimalsCells
    4. Cross-talk between mutant p53 and p62/SQSTM1 augments cancer cell migration by promoting the degradation of cell adhesion proteins. Proc Natl Acad Sci U S A. 2022 04 26; 119(17):e2119644119. Mukherjee S, Maddalena M, Lü Y, Martinez S, Nataraj NB, Noronha A, Sinha S, Teng K, Cohen-Kaplan V, Ziv T, Arandkar S, Hassin O, Chatterjee R, Pirona AC, Shreberk-Shaked M, Gershoni A, Aylon Y, Elazar Z, Yarden Y, Schramek D, Oren M. PMID: 35439056; PMCID: PMC9173583.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    5. Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors. Cell Rep. 2022 02 22; 38(8):110418. Nataraj NB, Noronha A, Lee JS, Ghosh S, Mohan Raju HR, Sekar A, Zuckerman B, Lindzen M, Tarcitano E, Srivastava S, Selitrennik M, Livneh I, Drago-Garcia D, Rueda O, Caldas C, Lev S, Geiger T, Ciechanover A, Ulitsky I, Seger R, Ruppin E, Yarden Y. PMID: 35196484; PMCID: PMC8957480.
      View in: PubMed   Mentions: 15     Fields:    
    6. Engineered variants of the Ras effector protein RASSF5 (NORE1A) promote anticancer activities in lung adenocarcinoma. J Biol Chem. 2021 12; 297(6):101353. Singh A, Erijman A, Noronha A, Kumar H, Peleg Y, Yarden Y, Shifman JM. PMID: 34717958; PMCID: PMC8605244.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    7. PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR. Cell Rep. 2021 05 25; 35(8):109181. Ghosh S, Nataraj NB, Noronha A, Patkar S, Sekar A, Mukherjee S, Winograd-Katz S, Kramarski L, Verma A, Lindzen M, Garcia DD, Green J, Eisenberg G, Gil-Henn H, Basu A, Lender Y, Weiss S, Oren M, Lotem M, Geiger B, Ruppin E, Yarden Y. PMID: 34038737; PMCID: PMC8170369.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    8. Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Res. 2021 07 15; 81(14):3862-3875. Haga Y, Marrocco I, Noronha A, Uribe ML, Nataraj NB, Sekar A, Drago-Garcia D, Borgoni S, Lindzen M, Giri S, Wiemann S, Tsutsumi Y, Yarden Y. PMID: 33941614; PMCID: PMC7611293.
      View in: PubMed   Mentions: 4     Fields:    
    9. Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53. Oncogene. 2021 05; 40(21):3665-3679. Lindzen M, Ghosh S, Noronha A, Drago D, Nataraj NB, Leitner O, Carvalho S, Zmora E, Sapoznik S, Shany KB, Levanon K, Aderka D, Ramírez BS, Dahlhoff M, McNeish I, Yarden Y. PMID: 33941851; PMCID: PMC8154589.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    10. Time-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer. Cancers (Basel). 2020 Oct 11; 12(10). Borgoni S, Sofyali E, Soleimani M, Wilhelm H, Müller-Decker K, Will R, Noronha A, Beumers L, Verschure PJ, Yarden Y, Magnani L, van Kampen AHC, Moerland PD, Wiemann S. PMID: 33050633; PMCID: PMC7650760.
      View in: PubMed   Mentions: 5  
    11. Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies. Biochem Biophys Res Commun. 2019 05 21; 513(1):219-225. Maron R, Schechter B, Nataraj NB, Ghosh S, Romaniello D, Marrocco I, Noronha A, Carvalho S, Yarden Y, Sela M. PMID: 30952434.
      View in: PubMed   Mentions: 4     Fields:    Translation:Animals
    12. A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways. Clin Cancer Res. 2018 11 15; 24(22):5610-5621. Romaniello D, Mazzeo L, Mancini M, Marrocco I, Noronha A, Kreitman M, Srivastava S, Ghosh S, Lindzen M, Salame TM, Onn A, Bar J, Yarden Y. PMID: 29967248.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    13. Irreversible modifications of receptor tyrosine kinases. FEBS Lett. 2018 07; 592(13):2199-2212. Kreitman M, Noronha A, Yarden Y. PMID: 29790151.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    14. An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors. EMBO Mol Med. 2018 02; 10(2):294-308. Mancini M, Gal H, Gaborit N, Mazzeo L, Romaniello D, Salame TM, Lindzen M, Mahlknecht G, Enuka Y, Burton DG, Roth L, Noronha A, Marrocco I, Adreka D, Altstadter RE, Bousquet E, Downward J, Maraver A, Krizhanovsky V, Yarden Y. PMID: 29212784; PMCID: PMC5801506.
      View in: PubMed   Mentions: 26     Fields:    
    15. SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors. Sci Signal. 2018 01 30; 11(515). Roth L, Srivastava S, Lindzen M, Sas-Chen A, Sheffer M, Lauriola M, Enuka Y, Noronha A, Mancini M, Lavi S, Tarcic G, Pines G, Nevo N, Heyman O, Ziv T, Rueda OM, Gnocchi D, Pikarsky E, Admon A, Caldas C, Yarden Y. PMID: 29382783.
      View in: PubMed   Mentions: 32     Fields:    
    16. Biological implications and therapeutic significance of DNA methylation regulated genes in cervical cancer. Biochimie. 2016 Feb; 121:298-311. Bhat S, Kabekkodu SP, Noronha A, Satyamoorthy K. PMID: 26743075.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    Ashish's Networks
    Concepts (94)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (9)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-15-g9ae42700 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.